Research programme: myostatin - SYN X Pharma
Alternative Names: Myostatin research programme - SYN X PharmaLatest Information Update: 15 May 2007
At a glance
- Originator Universite de Liege
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Muscular atrophy; Myocardial infarction
Most Recent Events
- 07 Aug 2006 No development reported - Preclinical for Muscle wasting in Belgium (unspecified route)
- 07 Aug 2006 No development reported - Preclinical for Myocardial infarction in Belgium (unspecified route)
- 07 May 2004 SYN X Pharma has been acquired by Nanogen